N/A N=16 Prospective Use of Awake Endoscopy for Inspire Activation
Obstructive Sleep Apnea
Primary: Distribution of Electrode Configurations Resulting in Greatest Retropalatal Expansion Among Cohort Subjects — 7; 3; 3; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=368 Feasibility and Validation of a Standard Phenotyping Assessment Battery
Opioid-use Disorder · Cocaine Use Disorder · Marijuana Use Disorder
Primary: Retention — 4; 27; 10; 21 Participants
Phase 4 N=13 New Onset Type 1 Diabetes: Role of Exenatide
Type 1 Diabetes
Primary: The Role of Exenatide as Compared to Insulin Monotherapy in Reducing Postprandial Hyperglycemia.
Phase 2 N=219 A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis
Psoriatic Arthritis
Primary: Percentage of Participants Achieving an American College of Rheumatology 20 (ACR20) Response at Week 16 — 43.28; 64.52; 66.67; 74.58 Percentage of participants — p=0.1172
N/A N=32 Zimmer® MotionLoc® in Distal Tibia Fractures
Distal Tibia Fractures
Primary: Average Clinical Fracture Healing of the Tibia Using the Function Index for Trauma (FIX-IT) Score at 3 Months Follow-up — 7.5 score on scale
Phase 3 N=151 Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer
Biliary Tract Cancer
Primary: Objective Response Rate (ORR) - Part 1 — 0; 0; 6; 3 Participants
N/A N=36 Incentives to Decrease Opioid Use - Pilot
Substance-Related Disorders · Opioid-Related Disorders · Behavior Therapy
Primary: Continuous Abstinence From Opioid Use — 6; 5; 5 Participants
N/A N=150 Effect of Dexmedetomidine Combined With Low-dose Nalmefene on Preventing Remifentanil-induced Postoperative Hyperalgesia
Pain · Anesthesia
Primary: Mechanical Hyperalgesia Threshold on the Dominant Inner Forearm — 61.5; 88.2; 73.0; 67.2 g
Phase 3 N=175 ARTEMIS Peanut Allergy In Children
Peanut Allergy
Primary: The Proportion of Subjects Ages 4-17 Who Tolerated a Single Highest Dose of at Least 1000 mg in the Exit Oral Food Challenge. — 77; 1 Participants — p=<0.0001
Phase 3 N=709 Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality
Non Small Cell Lung Cancer
Primary: Lung Cancer Recurrence or Mortality - 2 Years — 80; 85 Participants — p=0.94
Phase 2 N=43 Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis
Myasthenia Gravis
Primary: Change From Baseline in Quantitative Myasthenia Gravis (QMG) Score to Visit 9 — -1.2; -1.8 scores on a scale — p==0.221
N/A N=54 Transitional Rehabilitation in CABG Patients
Coronary Artery Disease · Coronary Artery Bypass Graft Surgery
Primary: Short Physical Performance Battery — 7.33; 8.00; 11.44; 10.90 units on a scale
Phase 2 N=58 Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
Metastatic Thyroid Gland Carcinoma · Poorly Differentiated Thyroid Gland Carcinoma · Recurrent Thyroid Gland Carcinoma
Primary: Response at 6 Months — 7; 2 Participants — p=0.0787
N/A N=3,962 Evaluating Evidence-Based Quality Improvement of Comprehensive Women's Health Care Implementation in Low-Performing VAs
Comprehensive Care
Primary: Gender-sensitive Care Environment — 4.2; 3.3; 1.6; 1.4 score on a scale — p=0.623
Phase 2 N=26 Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Clinical Benefit Rate [CBR] — 12 Participants